{"organizations": [], "uuid": "cde8bce6738a5d02aad14dd81340f4500494c9fe", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "uk.reuters.com", "main_image": "https://s4.reutersmedia.net/resources/r/?m=02&d=20180425&t=2&i=1255202488&w=1200&r=LYNXMPEE3O10Z", "site_section": "http://feeds.reuters.com/reuters/UKTopNews/", "section_title": "Reuters: Top News", "url": "https://uk.reuters.com/article/us-gsk-results/currency-weighs-on-glaxosmithkline-first-quarter-sales-and-earnings-idUKKBN1HW1GI", "country": "US", "domain_rank": 408, "title": "Currency weighs on GlaxoSmithKline first-quarter sales and earnings", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-25T14:14:00.000+03:00", "replies_count": 0, "uuid": "cde8bce6738a5d02aad14dd81340f4500494c9fe"}, "author": "", "url": "https://uk.reuters.com/article/us-gsk-results/currency-weighs-on-glaxosmithkline-first-quarter-sales-and-earnings-idUKKBN1HW1GI", "ord_in_thread": 0, "title": "Currency weighs on GlaxoSmithKline first-quarter sales and earnings", "locations": [], "entities": {"persons": [], "locations": [{"name": "hounslow", "sentiment": "none"}, {"name": "london", "sentiment": "none"}, {"name": "london", "sentiment": "none"}, {"name": "britain", "sentiment": "none"}], "organizations": [{"name": "glaxosmithkline", "sentiment": "negative"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "thomson reuters", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "gsk", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 25, 2018 / 11:31 AM / a few seconds ago Currency weighs on GlaxoSmithKline first quarter sales and earnings Reuters Staff 1 Min Read \nLONDON (Reuters) - Drugmaker GlaxoSmithKline ( GSK.L ) reported a 2 percent fall in both sales and earnings in the first quarter on Wednesday as a stronger pound offset a promising start for its new shingles vaccine Shingrix. FILE PHOTO: The GlaxoSmithKline building is pictured in Hounslow, west London, Britain, June 18, 2013. REUTERS/Luke MacGregor/File Photo \nGSKâ€™s adjusted earnings per share were 24.6 pence on sales of 7.22 billion pounds ($10.07 billion). Analysts, on average, had forecast 24.25 pence and 7.24 billion pounds, according to Thomson Reuters data. \n($1 = 0.7168 pounds)", "external_links": [], "published": "2018-04-25T14:14:00.000+03:00", "crawled": "2018-04-25T14:44:01.012+03:00", "highlightTitle": ""}